Designed for advanced Parkinson’s with poorly controlled motor fluctuations, the infusion delivers steadier levodopa exposure than pills via continuous subcutaneous dosing.
As multiple drugmakers race to bring novel, levodopa-based Parkinson’s disease treatments to the market, New Jersey’s Amneal Pharmaceuticals has taken home the gold in the U.S. Late Wednesday, the FDA ...
A study involving 22 Parkinson's disease (PD) patients has shown that use of the dopaminergic drug levodopa improves sleep quality. When the patients took the drug, the number of times they woke up ...
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with advanced Parkinson’s disease. This novel treatment is the first of its kind, ...
The US Food and Drug Administration (FDA) has approved foscarbidopa and foslevodopa (Vyalev, AbbVie), a solution of carbidopa and levodopa prodrugs for 24-hour continuous subcutaneous infusion, for ...
CREXONT ® is a novel, oral formulation of carbidopa/levodopa (CD/LD) capsule that combines both immediate-release granules and extended-release beads for the treatment of Parkinson’s disease. CREXONT ...
Researchers uncovered new findings about involuntary muscle movements that come with long-term administration of Parkinson's drug levodopa. University of Arizona researchers have revealed new insights ...
The FDA extended its decision date for investigational tolebrutinib in non-relapsing, secondary progressive multiple sclerosis (MS) to December 28, Sanofi said. The agency also opted to not approve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results